Difficulty: Medium
Average Score: 63%
Practice
An 83-year-old woman with Parkinson's disease is currently being treated with carbidopa/levodopa, but her Parkinson's symptoms are worsening. She has normal liver function and no history of liver disease. Selegiline is added to her regimen. How does selegiline help in Parkinson's disease?
Correct answer
C
Rationale
In the context of treating Parkinson's disease, the addition of selegiline to a patient's regimen is aimed at providing symptomatic relief by inhibiting monoamine oxidase (MAO). MAO is an enzyme that breaks down neurotransmitters like dopamine in the brain. By inhibiting MAO, selegiline helps to increase dopamine levels in the brain, which is crucial in managing the symptoms of Parkinson's disease, as the condition is characterized by a deficiency of dopamine.
Option A, increased norepinephrine synthesis, is incorrect because selegiline does not directly impact norepinephrine synthesis. Option B, inhibition of COMT, is incorrect as selegiline does not inhibit catechol-O-methyltransferase (COMT), which is another enzyme involved in the breakdown of catecholamines in the body. Option D, stimulation of acetylcholine release, is also incorrect as selegiline does not directly stimulate acetylcholine release.
Understanding the mechanism of action of medications used in treating neurological disorders like Parkinson's disease is crucial for healthcare providers to make informed decisions regarding patient care. By grasping the pharmacological principles behind drug actions, healthcare professionals can optimize treatment plans, minimize adverse effects, and improve patient outcomes.
Option A, increased norepinephrine synthesis, is incorrect because selegiline does not directly impact norepinephrine synthesis. Option B, inhibition of COMT, is incorrect as selegiline does not inhibit catechol-O-methyltransferase (COMT), which is another enzyme involved in the breakdown of catecholamines in the body. Option D, stimulation of acetylcholine release, is also incorrect as selegiline does not directly stimulate acetylcholine release.
Understanding the mechanism of action of medications used in treating neurological disorders like Parkinson's disease is crucial for healthcare providers to make informed decisions regarding patient care. By grasping the pharmacological principles behind drug actions, healthcare professionals can optimize treatment plans, minimize adverse effects, and improve patient outcomes.